April 1, 2020 10:34 AM EDT

FDA puts pediatric aGVHD drug on priority review lane — will they go virtual with the adcomm?

Amber Tong

Despite worries about regulatory delays due to new work arrangements under Covid-19, the FDA appears intent to go full speed ahead with its everyday work …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA puts pediatric aGVHD drug on priority review lane — will they go virtual with the adcomm?

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Novartis claims best earnings in years, validating shift to pure-play strategy

Roche separates CFO, informatics posts; Lilly execs land at Kailera, Neurocrine

Vertex's non-opioid pain drug is approved by FDA, bringing first of new class to market

Friday IPO doubleheader from Maze and Metsera brings life to biotech debuts

AbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

FDA puts pe­di­atric aGVHD drug on pri­or­i­ty re­view lane — will they go vir­tu­al with the ad­comm?

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA puts pediatric aGVHD drug on priority review lane — will they go virtual with the adcomm?